- Home
- ARDX
ARDX
Ardelyx Inc.
as 07-04-2025 11:30am EST
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Founded: | 2007 | Country: | United States |
| Employees: | 395 | City: | FREMONT |
| Market Cap: | 882.9M | IPO Year: | 2014 |
| Target Price: | $10.17 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $7.18 | Next Earning Date: | 07-31-2025 |
| Revenue: | $361,706,000 | Revenue Growth: | 127.33% |
| Revenue Growth (this year): | 12.01% | Revenue Growth (next year): | 34.66% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOTT DAVID M | ARDX | Director | Jun 16 '25 | Buy | $3.63 | 200,000 | $725,880.00 | 2,896,871 | |
| MOTT DAVID M | ARDX | Director | Jun 9 '25 | Buy | $3.69 | 200,000 | $737,260.00 | 2,896,871 | |
| RAAB MICHAEL | ARDX | President & CEO | May 20 '25 | Sell | $4.08 | 46,817 | $191,078.90 | 1,547,937 | |
| Renz Justin A | ARDX | Chief Financial Officer | May 20 '25 | Sell | $4.08 | 7,218 | $29,459.55 | 416,089 | |
| Williams Laura A | ARDX | Chief Medical Officer | May 20 '25 | Sell | $4.08 | 6,421 | $26,206.67 | 402,583 | |
| Kelliher Mike | ARDX | See Remarks | May 20 '25 | Sell | $4.08 | 14,522 | $59,270.09 | 282,158 | |
| GRAMMER ELIZABETH A | ARDX | See Remarks | May 20 '25 | Sell | $4.08 | 5,992 | $24,455.75 | 311,731 | |
| Foster Eric Duane | ARDX | Chief Commercial Officer | May 20 '25 | Sell | $4.08 | 2,507 | $10,232.07 | 316,806 | |
| MOTT DAVID M | ARDX | Director | May 15 '25 | Buy | $3.29 | 100,000 | $329,120.00 | 2,896,871 | |
| MOTT DAVID M | ARDX | Director | May 2 '25 | Buy | $4.22 | 381,377 | $1,610,936.45 | 2,896,871 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Exploring Three High Growth Tech Stocks in the US Market
Simply Wall St.
10 days ago
Exploring US High Growth Tech Stocks For Potential Opportunities
Insider Monkey
10 days ago
H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy
Simply Wall St.
10 days ago
US High Growth Tech Stocks To Watch In June 2025
Insider Monkey
11 days ago
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT
Simply Wall St.
11 days ago
High Growth Tech Stocks To Watch In US June 2025
Simply Wall St.
11 days ago
Ardelyx Leads The Pack Of 3 Promising Penny Stocks
Simply Wall St.
11 days ago
Exploring US High Growth Tech Stocks To Watch In June 2025
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.